BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27731926)

  • 1. Mutation analysis of the EGFR gene and its downstream signaling pathway in thymic carcinoma patients from a Chinese Han population.
    Zhan P; Chen X; Wu XY; Hou ZB; Qian Q; Zhang Y; Zou J; Zhang YQ; Wan MY; Wang JD; Yu LK; Xie HY
    Clin Respir J; 2018 Feb; 12(2):601-607. PubMed ID: 27731926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.
    Sakane T; Murase T; Okuda K; Saida K; Masaki A; Yamada T; Saito Y; Nakanishi R; Inagaki H
    Histopathology; 2019 Nov; 75(5):755-766. PubMed ID: 31179560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
    Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
    Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.
    Mezzapelle R; Miglio U; Rena O; Paganotti A; Allegrini S; Antona J; Molinari F; Frattini M; Monga G; Alabiso O; Boldorini R
    Br J Cancer; 2013 Apr; 108(8):1743-9. PubMed ID: 23558893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
    Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.
    Tahara I; Oishi N; Mochizuki K; Oyama T; Miyata K; Miyauchi A; Hirokawa M; Katoh R; Kondo T
    Endocr Pathol; 2020 Sep; 31(3):274-282. PubMed ID: 32594366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers.
    Liao W; Liao Y; Zhou JX; Xie J; Chen J; Huang W; Luo R
    Anat Rec (Hoboken); 2010 Sep; 293(9):1506-11. PubMed ID: 20652941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TP53 and EGFR Mutational Status in Thymoma: A Genetic Sequencing Study.
    Syahruddin E; Zaini J; Sembiring R; Baginta R; Fadhillah MR; Noor DR
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):109-114. PubMed ID: 35092378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation Profile of Thymic Carcinoma and Thymic Neuroendocrine Tumor by Targeted Next-generation Sequencing.
    Sakane T; Sakamoto Y; Masaki A; Murase T; Okuda K; Nakanishi R; Inagaki H
    Clin Lung Cancer; 2021 Mar; 22(2):92-99.e4. PubMed ID: 33414055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
    Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
    Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-related gene expression levels in thymic carcinoma and Type B3 thymoma.
    Karube Y; Kobayashi S; Maeda S; Sado T; Ishihama H; Chida M
    J Cardiothorac Surg; 2016 May; 11(1):85. PubMed ID: 27387303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.
    de Vries M; Bruijn IB; Cleton-Jansen AM; Malessy MJ; van der Mey AG; Hogendoorn PC
    Virchows Arch; 2013 Feb; 462(2):211-7. PubMed ID: 23224067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.
    Mimae T; Tsuta K; Kondo T; Nitta H; Grogan TM; Okada M; Asamura H; Tsuda H
    Ann Oncol; 2012 Dec; 23(12):3129-3137. PubMed ID: 22700994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.